Recent Research Highlights Potential Benefits of GLP-1 Receptor Agonists Across Multiple Patient Populations
New findings from several major studies have linked glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to improved health outcomes in diverse patient groups. The research, comprising cohort analyses and a post-hoc trial evaluation, points to potential advantages for breast cancer patients with obesity, diabetic patients with a history of limb events, and those with both diabetes and cardiovascular disease.
Breast Cancer Patients with Obesity
A cohort study involving breast cancer patients found an association between the use of GLP-1 RAs and improved outcomes in patients diagnosed with obesity and related metabolic conditions.
The study's authors stated that the results indicate a need for further evaluation of GLP-1 RA therapy through randomized clinical trials.
Diabetic Patients with a History of Major Adverse Limb Events
A nationwide cohort study examined patients with diabetes who had a history of major adverse limb events. The study compared outcomes for patients treated with GLP-1 RAs against those treated with dipeptidyl peptidase-4 inhibitors.
The research reported that treatment with GLP-1 RAs was associated with a statistically significant reduction in risk for the following complications:
- Recurrent limb events
- Cardiovascular events
- All-cause mortality
- Kidney disease progression
The authors of the study advocated for the preferred use of GLP-1 RAs for secondary prevention in this high-risk patient population.
Patients with Diabetes and Established Cardiovascular Disease
A post hoc analysis compared the dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide agonist tirzepatide with the GLP-1 agonist dulaglutide.
The analysis indicated that tirzepatide was associated with a lower incidence of a broad 6-component composite cardiovascular and kidney endpoint.
This finding was observed in patients diagnosed with diabetes and established cardiovascular disease.